Advances in personalized targeted treatment of metastatic melanoma and non-invasive tumor monitoring

Frontiers in Oncology

Volumn 3 MAR, Issue , 2013, Pages

  Klinac, Dragana ^a   Gray, Elin S ^a   Millward, Michael ^b   Ziman, Mel ^a,c  

^a EDITH COWAN UNIVERSITY   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Circulating tumor cells; Drug resistance; Metastatic melanoma; Personalized treatment; Targeted therapy

Indexed keywords

ARRY 438162; BEVACIZUMAB; BOSUTINIB; CAPECITABINE; CARBOPLATIN; CHIR 265; DABRAFENIB; DACARBAZINE; DASATINIB; EVEROLIMUS; FOTEMUSTINE; IMATINIB; IPILIMUMAB; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE; N (2, 3 DIHYDROXYPROPOXY) 3, 4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO) BENZAMIDE; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; NILOTINIB; PACLITAXEL; SELUMETINIB; SORAFENIB; SUNITINIB; TEMOZOLOMIDE; TEMSIROLIMUS; TRAMETINIB; UNCLASSIFIED DRUG; VEMURAFENIB;

APOPTOSIS; ARTHRALGIA; BILIARY TRACT CANCER; CELL CYCLE ARREST; CIRCULATING TUMOR CELL; DIARRHEA; DRUG EFFICACY; EDEMA; FATIGUE; GASTROINTESTINAL STROMAL TUMOR; GENE MUTATION; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; METASTATIC MELANOMA; MOLECULARLY TARGETED THERAPY; NAUSEA; NONHUMAN; OVERALL SURVIVAL; PATIENT MONITORING; PERSONALIZED MEDICINE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHOTOSENSITIVITY; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RASH; REVIEW; TUMOR GROWTH;

EID: 84879679714     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2013.00054     Document Type: Review

References (131)

1. Anforth, R. M., Blumetti, T. C., Kefford, R. F., Sharma, R., Scolyer, R. A., Kossard, S., et al. (2012). Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma. Br. J. Dermatol. 167, 1153-1160.
2. Artale, S., Sartore-Bianchi, A., Veronese, S. M., Gambi, V., Sarnataro, C. S., Gambacorta, M., et al. (2008). Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer. J. Clin. Oncol. 26, 4217-4219.
3. Attard, G., Swennenhuis, J. F., Olmos, D., Reid, A. H., Vickers, E., A'Hern, R., et al. (2009). Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer. Cancer Res. 69, 2912-2918.
4. Berger, M. F., Hodis, E., Heffernan, T. P., Deribe, Y. L., Lawrence, M. S., Protopopov, A., et al. (2012). Melanoma genome sequencing reveals frequent PREX2 mutations. Nature 485, 502-506.
5. Bollag, G., Hirth, P., Tsai, J., Zhang, J., Ibrahim, P. N., Cho, H., et al. (2010). Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 467, 596-599.
6. Brahmer, J. R., Drake, C. G., Wollner, I., Powderly, J. D., Picus, J., Sharfman, W. H., et al. (2010). Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J. Clin. Oncol. 28, 3167-3175.
7. Brahmer, J. R., Tykodi, S. S., Chow, L. Q., Hwu, W. J., Topalian, S. L., Hwu, P., et al. (2012). Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366, 2455-2465.
8. Carvajal, R. D., Antonescu, C. R., Wolchok, J. D., Chapman, P. B., Roman, R. A., Teitcher, J., et al. (2011). KIT as a therapeutic target in metastatic melanoma. JAMA 305, 2327-2334.
9. Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., et al. (2011). Improved survival with Vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364, 2507-2516.
10. Chapman, P. B., Hauschild, A., Robert, C., Larkin, J., Haanen, J. B., Ribas, A., et al. (2012). Updated overall survival (OS) results for BRIM-3, a phase III randomized, open-label, multicenter trial comparing BRAF inhibitor vemurafenib (vem) with dacarbazine (DTIC) in previously untreated patients with BRAFV600E-mutated melanoma. Melanoma/Skin Cancers 2012 ASCO Annual Meeting. J. Clin. Oncol. 30(Suppl.), :abstr 8502.
11. Chappell, W. H., Steelman, L. S., Long, J. M., Kempf, R. C., Abrams, S. L., Franklin, R. A., et al. (2011). Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health. Oncotarget 2, 135-164.
12. Chow, L. Q., and Eckhardt, S. G. (2007). Sunitinib: from rational design to clinical efficacy. J. Clin. Oncol. 25, 884-896.
13. Cohen, S. J., Punt, C. J., Iannotti, N., Saidman, B. H., Sabbath, K. D., Gabrail, N. Y., et al. (2008). Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J. Clin. Oncol. 26, 3213-3221.
14. Colombino, M., Capone, M., Lissia, A., Cossu, A., Rubino, C., De Giorgi, V., et al. (2012). BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma. J. Clin. Oncol. 30, 2522-2529.
15. Corcoran, R. B., Ebi, H., Turke, A. B., Coffee, E. M., Nishino, M., Cogdill, A. P., et al. (2012). EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discov. 2, 227-235.
16. Cristofanilli, M., Budd, G. T., Ellis, M. J., Stopeck, A., Matera, J., Miller, M. C., et al. (2004). Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N. Engl. J. Med. 351, 781-791.
17. Curtin, J. A., Fridlyand, J., Kageshita, T., Patel, H. N., Busam, K. J., Kutzner, H., et al. (2005). Distinct sets of genetic alterations in melanoma. N. Engl. J. Med. 353, 2135-2147.
18. Davies, B. R., Logie, A., McKay, J. S., Martin, P., Steele, S., Jenkins, R., et al. (2007). AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models. Mol. Cancer Ther. 6, 2209-2219.
19. Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., et al. (2002). Mutations of the BRAF gene in human cancer. Nature 417, 949-954.
20. de Bono, J. S., Scher, H. I., Montgomery, R. B., Parker, C., Miller, M. C., Tissing, H., et al. (2008). Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin. Cancer Res. 14, 6302-6309.
21. Deenen, M. J., Klumpen, H. J., Richel, D. J., Sparidans, R. W., Weterman, M. J., Beijnen, J. H., et al. (2012). Phase I and pharmacokinetic study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced solid malignancies. Invest. New Drugs 30, 1557-1565.
22. Di Giacomo, A. M., Ascierto, P. A., Pilla, L., Santinami, M., Ferrucci, P. F., Giannarelli, D., et al. (2012). Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial. Lancet Oncol. 13, 879-886.
23. Dong, H., Zhu, G., Tamada, K., and Chen, L. (1999). B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat. Med. 5, 1365-1369.
24. Dong, J., Phelps, R. G., Qiao, R., Yao, S., Benard, O., Ronai, Z., et al. (2003). BRAF oncogenic mutations correlate with progression rather than initiation of human melanoma. Cancer Res. 63, 3883-3885.
25. Dronca, R. S., Perez, D. G., Allred, J., Maples, W. J., Creagan, E. T., Pockaj, B. A., et al. (2010). N0675: NCCTG phase II study of temozolomide (TMZ) and everolimus (RAD001) therapy for metastatic melanoma (MM). Melanoma/Skin Cancers 2010 ASCO Annual Meeting. J. Clin. Oncol. 28(Suppl. 15s), :abstr 8572.
26. Dummer, R., Robert, C., Chapman, P. B., Sosman, J. A., Middleton, M., Bastholt, L., et al. (2008). AZD6244 (ARRY-142886) vs temozolomide (TMZ) in patients (pts) with advanced melanoma: an open-label, randomized, multicenter, phase II study. Melanoma/Skin Cancers 2008 ASCO Annual Meeting. J. Clin. Oncol. 26(Suppl.), :abstr 9033.
27. Dutton-Regester, K., and Hayward, N. K. (2012). Reviewing the somatic genetics of melanoma: from current to future analytical approaches. Pigment Cell Melanoma Res. 25, 144-154.
28. Eigentler, T. K., Figl, A., Krex, D., Mohr, P., Mauch, C., Rass, K., et al. (2011). Number of metastases, serum lactate dehydrogenase level, and type of treatment are prognostic factors in patients with brain metastases of malignant melanoma. Cancer 117, 1697-1703.
29. Eisen, T., Ahmad, T., Flaherty, K. T., Gore, M., Kaye, S., Marais, R., et al. (2006). Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis. Br. J. Cancer 95, 581-586.
30. Escudier, B., Eisen, T., Stadler, W. M., Szczylik, C., Oudard, S., Siebels, M., et al. (2007). Sorafenib in advanced clear-cell renal-cell carcinoma. N. Engl. J. Med. 356, 125-134.
31. Eskandarpour, M., Kiaii, S., Zhu, C., Castro, J., Sakko, A. J., and Hansson, J. (2005). Suppression of oncogenic NRAS by RNA interference induces apoptosis of human melanoma cells. Int. J. Cancer 115, 65-73.
32. Falchook, G. S., Lewis, K. D., Infante, J. R., Gordon, M. S., Vogelzang, N. J., Demarini, D. J., et al. (2012a). Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. Lancet Oncol. 13, 782-789.
33. Falchook, G. S., Long, G. V., Kurzrock, R., Kim, K. B., Arkenau, T. H., Brown, M. P., et al. (2012b). Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet 379, 1893-1901.
34. Fecher, L. A., Cummings, S. D., Keefe, M. J., and Alani, R. M. (2007). Toward a molecular classification of melanoma. J. Clin. Oncol. 25, 1606-1620.
35. Finn, R. S., Javie, B. R., Tan, J., Weekes, C. C., Bendell, J. C., Patnaik, A., et al. (2012). A phase I study of MEK inhibitor MEK162 (ARRY-438162) in patients with biliary tract cancer. ASCO 2012 Gastrointestinal Cancers Symposium. J. Clin. Oncol. 30(Suppl. 4), :abstr 220.
36. Flaherty, K. T. (2006). Chemotherapy and targeted therapy combinations in advanced melanoma. Clin. Cancer Res. 12, 2366s-2370s.
37. Flaherty, K. T., Infante, J. R., Daud, A., Gonzalez, R., Kefford, R. F., Sosman, J., et al. (2012a). Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N. Engl. J. Med. 367, 1694-1703.
38. Flaherty, K. T., Robert, C., Hersey, P., Nathan, P., Garbe, C., Milhem, M., et al. (2012b). Improved survival with MEK inhibition in BRAF-mutated melanoma. N. Engl. J. Med. 367, 107-114.
39. Flores, J. F., Walker, G. J., Glendening, J. M., Haluska, F. G., Castresana, J. S., Rubio, M. P., et al. (1996). Loss of the p16INK4a and p15INK4b genes, as well as neighboring 9p21 markers, in sporadic melanoma. Cancer Res. 56, 5023-5032.
40. Fox, M. C., Lao, C. D., Schwartz, J. L., Frohm, M. L., Bichakjian, C. K., and Johnson, T. M. (2013). Management options for metastatic melanoma in the era of novel therapies: a primer for the practicing dermatologist: part II: management of stage IV disease. J. Am. Acad. Dermatol. 68, 13.e11-e13.
41. Freeman, J. B., Gray, E. S., Millward, M., Pearce, R., and Ziman, M. (2012). Evaluation of a multi-marker immunomagnetic enrichment assay for the quantification of circulating melanoma cells. J. Transl. Med. 10, 192.
42. Fusi, A., Berdel, R., Havemann, S., Nonnenmacher, A., and Keilholz, U. (2011). Enhanced detection of BRAF-mutants by pre-PCR cleavage of wild-type sequences revealed circulating melanoma cells heterogeneity. Eur. J. Cancer 47, 1971-1976.
43. Fusi, A., Liu, Z., Kummerlen, V., Nonnemacher, A., Jeske, J., and Keilholz, U. (2012). Expression of chemokine receptors on circulating tumor cells in patients with solid tumors. J. Transl. Med. 10, 52.
44. Gajewski, T. F., Niedzwiecki, D., Johnson, A. W., Linette, G., Bucher, C., Blaskovich, M., et al. (2006). Phase II study of the farnesyltransferase inhibitor R115777 in advanced melanoma: CALGB 500104. ASCO Annual Meeting Proceedings Part I. J. Clin. Oncol. 24(Suppl. 18S), :abstr 8014.
45. Gartside, M. G., Chen, H., Ibrahimi, O. A., Byron, S. A., Curtis, A. V., Wellens, C. L., et al. (2009). Loss-of-function fibroblast growth factor receptor-2 mutations in melanoma. Mol. Cancer Res. 7, 41-54.
46. Gray-Schopfer, V. C., Karasarides, M., Hayward, R., and Marais, R. (2007). Tumor necrosis factor-alpha blocks apoptosis in melanoma cells when BRAF signaling is inhibited. Cancer Res. 67, 122-129.
47. Guo, J., Si, L., Kong, Y., Flaherty, K. T., Xu, X., Zhu, Y., et al. (2011). Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. J. Clin. Oncol. 29, 2904-2909.
48. Hamid, O. (2012). Efficacy and safety of MK-3475 in patients with advanced melanoma, Society for Melanoma Research 2012 Congress. Pigment Cell & Melanoma Research 26, 150-155.
49. Hauschild, A., Grob, J. J., Demidov, L. V., Jouary, T., Gutzmer, R., Millward, M., et al. (2012). Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 380, 358-365.
50. Hidalgo, M., and Rowinsky, E. K. (2000). The rapamycin-sensitive signal transduction pathway as a target for cancer therapy. Oncogene 19, 6680-6686.
51. Hodi, F. S., Friedlander, P., Corless, C. L., Heinrich, M. C., Mac Rae, S., Kruse, A., et al. (2008). Major response to imatinib mesylate in KIT-mutated melanoma. J. Clin. Oncol. 26, 2046-2051.
52. Hodi, F. S., O'day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., et al. (2010). Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711-723.
53. Hodis, E., Watson, I. R., Kryukov, G. V., Arold, S. T., Imielinski, M., Theurillat, J. P., et al. (2012). A landscape of driver mutations in melanoma. Cell 150, 251-263.
54. Hoshimoto, S., Faries, M. B., Morton, D. L., Shingai, T., Kuo, C., Wang, H. J., et al. (2012). Assessment of prognostic circulating tumor cells in a phase III trial of adjuvant immunotherapy after complete resection of stage IV melanoma. Ann. Surg. 255, 357-362.
55. Huang, S., and Houghton, P. J. (2003). Targeting mTOR signaling for cancer therapy. Curr. Opin. Pharmacol. 3, 371-377.
56. Italiano, A., Hostein, I., Soubeyran, I., Fabas, T., Benchimol, D., Evrard, S., et al. (2010). KRAS and BRAF mutational status in primary colorectal tumors and related metastatic sites: biological and clinical implications. Ann. Surg. Oncol. 17, 1429-1434.
57. Iwai, Y., Ishida, M., Tanaka, Y., Okazaki, T., Honjo, T., and Minato, N. (2002). Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc. Natl. Acad. Sci. U.S.A. 99, 12293-12297.
58. Johannessen, C. M., Boehm, J. S., Kim, S. Y., Thomas, S. R., Wardwell, L., Johnson, L. A., et al. (2010). COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 468, 968-972.
59. Kantarjian, H., Giles, F., Wunderle, L., Bhalla, K., O'Brien, S., Wassmann, B., et al. (2006). Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N. Engl. J. Med. 354, 2542-2551.
60. Khoja, L., Lorigan, P., Zhou, C., Lancashire, M., Booth, J., Cummings, J., et al. (2012). Biomarker utility of circulating tumor cells in metastatic cutaneous melanoma. J. Invest. Dermatol. doi:10.1038/jid.2012.468
61. Kim, K. B., Lewis, K., Pavlick, A., Infante, J. R., Ribas, A., Sosman, J. A., et al. (2011). A phase II study of the MEK1/MEK2 inhibitor GSK1120212 in metastatic BRAF-V600E or K mutant cutaneous melanoma patients previously treated with or without a BRAF inhibitor. 2011 International Melanoma Congress. Pigment Cell Res. 24, 990-1075 (abstr; LBA1-3).
62. Kitago, M., Koyanagi, K., Nakamura, T., Goto, Y., Faries, M., O'Day, S. J., et al. (2009). mRNA expression and BRAF mutation in circulating melanoma cells isolated from peripheral blood with high molecular weight melanoma-associated antigen-specific monoclonal antibody beads. Clin. Chem. 55, 757-764.
63. Kluger, H. M., Dudek, A. Z., McCann, C., Ritacco, J., Southard, N., Jilaveanu, L. B., et al. (2011). A phase 2 trial of dasatinib in advanced melanoma. Cancer 117, 2202-2208.
64. Koyanagi, K., O'Day, S. J., Boasberg, P., Atkins, M. B., Wang, H. J., Gonzalez, R., et al. (2010). Serial monitoring of circulating tumor cells predicts outcome of induction biochemotherapy plus maintenance biotherapy for metastatic melanoma. Clin. Cancer Res. 16, 2402-2408.
65. Krauthammer, M., Kong, Y., Ha, B. H., Evans, P., Bacchiocchi, A., McCusker, J. P., et al. (2012). Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma. Nat. Genet. 44, 1006-1014.
66. Krebs, M. G., Sloane, R., Priest, L., Lancashire, L., Hou, J. M., Greystoke, A., et al. (2011). Evaluation and prognostic significance of circulating tumor cells in patients with non-small-cell lung cancer. J. Clin. Oncol. 29, 1556-1563.
67. Lasithiotakis, K. G., Sinnberg, T. W., Schittek, B., Flaherty, K. T., Kulms, D., MacZey, E., et al. (2008). Combined inhibition of MAPK and mTOR signaling inhibits growth, induces cell death, and abrogates invasive growth of melanoma cells. J. Invest. Dermatol. 128, 2013-2023.
68. Leversha, M. A., Han, J., Asgari, Z., Danila, D. C., Lin, O., Gonzalez-Espinoza, R., et al. (2009). Fluorescence in situ hybridization analysis of circulating tumor cells in metastatic prostate cancer. Clin. Cancer Res. 15, 2091-2097.
69. Liegl, B., Kepten, I., Le, C., Zhu, M., Demetri, G. D., Heinrich, M. C., et al. (2008). Heterogeneity of kinase inhibitor resistance mechanisms in GIST. J. Pathol. 216, 64-74.
70. Linos, E., Swetter, S. M., Cockburn, M. G., Colditz, G. A., and Clarke, C. A. (2009). Increasing burden of melanoma in the United States. J. Invest. Dermatol. 129, 1666-1674.
71. Lo, R. S. (2012). Receptor tyrosine kinases in cancer escape from BRAF inhibitors. Cell Res. 22, 945-947.
72. Lombardo, L. J., Lee, F. Y., Chen, P., Norris, D., Barrish, J. C., Behnia, K., et al. (2004). Discovery of N-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino) thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J. Med. Chem. 47, 6658-6661.
73. Long, G. V., Trefzer, U., Davies, M. A., Kefford, R. F., Ascierto, P. A., Chapman, P. B., et al. (2012). Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol. 13, 1087-1095.
74. Lorusso, P. M., Adjei, A. A., Varterasian, M., Gadgeel, S., Reid, J., Mitchell, D. Y., et al. (2005). Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies. J. Clin. Oncol. 23, 5281-5293.
75. Lu, Y., Yu, Q., Liu, J. H., Zhang, J., Wang, H., Koul, D., et al. (2003). Src family protein-tyrosine kinases alter the function of PTEN to regulate phosphatidylinositol 3-kinase/AKT cascades. J. Biol. Chem. 278, 40057-40066.
76. Maheswaran, S., Sequist, L. V., Nagrath, S., Ulkus, L., Brannigan, B., Collura, C. V., et al. (2008). Detection of mutations in EGFR in circulating lung-cancer cells. N. Engl. J. Med. 359, 366-377.
77. Manley, P. W., Stiefl, N., Cowan-Jacob, S. W., Kaufman, S., Mestan, J., Wartmann, M., et al. (2010). Structural resemblances and comparisons of the relative pharmacological properties of imatinib and nilotinib. Bioorg. Med. Chem. 18, 6977-6986.
78. Margolin, K., Longmate, J., Baratta, T., Synold, T., Christensen, S., Weber, J., et al. (2005). CCI-779 in metastatic melanoma: a phase II trial of the California Cancer Consortium. Cancer 104, 1045-1048.
79. Meier, F., Busch, S., Lasithiotakis, K., Kulms, D., Garbe, C., MacZey, E., et al. (2007). Combined targeting of MAPK and AKT signalling pathways is a promising strategy for melanoma treatment. Br. J. Dermatol. 156, 1204-1213.
80. Meier, F., Schittek, B., Busch, S., Garbe, C., Smalley, K., Satyamoorthy, K., et al. (2005). The RAS/RAF/MEK/ERK and PI3K/AKT signaling pathways present molecular targets for the effective treatment of advanced melanoma. Front. Biosci. 10, 2986-3001.
81. Menzies, A. M., Haydu, L. E., Visintin, L., Carlino, M. S., Howle, J. R., Thompson, J. F., et al. (2012). Distinguishing clinicopathologic features of patients with V600E and V600K BRAF-mutant metastatic melanoma. Clin. Cancer Res. 18, 3242-3249.
82. Minor, D. R., Kashani-Sabet, M., Garrido, M., O'Day, S. J., Hamid, O., and Bastian, B. C. (2012). Sunitinib therapy for melanoma patients with KIT mutations. Clin. Cancer Res. 18, 1457-1463.
83. Molhoek, K. R., Brautigan, D. L., and Slingluff, C. L. Jr. (2005). Synergistic inhibition of human melanoma proliferation by combination treatment with B-Raf inhibitor BAY43-9006 and mTOR inhibitor Rapamycin. J. Transl. Med. 3, 39.
84. Murugan, A. K., Dong, J., Xie, J., and Xing, M. (2009). MEK1 mutations, but not ERK2 mutations, occur in melanomas and colon carcinomas, but none in thyroid carcinomas. Cell Cycle 8, 2122-2124.
85. Nazarian, R., Shi, H., Wang, Q., Kong, X., Koya, R. C., Lee, H., et al. (2010). Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 468, 973-977.
86. Nezos, A., Lembessis, P., Sourla, A., Pissimissis, N., Gogas, H., and Koutsilieris, M. (2009). Molecular markers detecting circulating melanoma cells by reverse transcription polymerase chain reaction: methodological pitfalls and clinical relevance. Clin. Chem. Lab. Med. 47, 1-11.
87. Omholt, K., Krockel, D., Ringborg, U., and Hansson, J. (2006). Mutations of PIK3CA are rare in cutaneous melanoma. Melanoma Res. 16, 197-200.
88. Ott, P. A., Hamilton, A., Min, C., Safarzadeh-Amiri, S., Goldberg, L., Yoon, J., et al. (2010). A phase II trial of sorafenib in metastatic melanoma with tissue correlates. PLoS ONE 5:e15588. doi:10.1371/journal.pone.0015588
89. Paraiso, K. H., Xiang, Y., Rebecca, V. W., Abel, E. V., Chen, Y. A., Munko, A. C., et al. (2011). PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression. Cancer Res. 71, 2750-2760.
90. Pavlu, J., and Marin, D. (2009). Dasatinib and chronic myeloid leukemia: two-year follow-up in eight clinical trials. Clin. Lymphoma Myeloma 9, 417-424.
91. Pecuchet, N., Lebbe, C., Mir, O., Billemont, B., Blanchet, B., Franck, N., et al. (2012). Sorafenib in advanced melanoma: a critical role for pharmacokinetics? Br. J. Cancer 107, 455-461.
92. Poulikakos, P. I., Persaud, Y., Janakiraman, M., Kong, X., Ng, C., Moriceau, G., et al. (2011). RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature 480, 387-390.
93. Prahallad, A., Sun, C., Huang, S., Di Nicolantonio, F., Salazar, R., Zecchin, D., et al. (2012). Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 483, 100-103.
94. Prickett, T. D., Agrawal, N. S., Wei, X., Yates, K. E., Lin, J. C., Wunderlich, J. R., et al. (2009). Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4. Nat. Genet. 41, 1127-1132.
95. Prickett, T. D., Wei, X., Cardenas-Navia, I., Teer, J. K., Lin, J. C., Walia, V., et al. (2011). Exon capture analysis of G protein-coupled receptors identifies activating mutations in GRM3 in melanoma. Nat. Genet. 43, 1119-1126.
96. Reid, A. L., Millward, M., Pearce, R., Lee, M., Frank, M. H., Ireland, A., et al. (2013). Markers of circulating tumour cells in the peripheral blood of patients with melanoma correlate with disease recurrence and progression. Br. J. Dermatol. 168, 85-92.
97. Reynolds, S. R., Albrecht, J., Shapiro, R. L., Roses, D. F., Harris, M. N., Conrad, A., et al. (2003). Changes in the presence of multiple markers of circulating melanoma cells correlate with clinical outcome in patients with melanoma. Clin. Cancer Res. 9, 1497-1502.
98. Ribas, A. (2012). Tumor immunotherapy directed at PD-1. N. Engl. J. Med. 366, 2517-2519.
99. Robert, C., Flaherty, K. T., Hersey, P., Nathan, P., Garbe, C., Milhem, M. M., et al. (2012). METRIC phase III study: efficacy of trametinib (T), a potent and selective MEK inhibitor (MEKi), in progression-free survival (PFS) and overall survival (OS), compared with chemotherapy (C) in patients (pts) with BRAFV600E/K mutant advanced or metastatic melanoma (MM). Melanoma/Skin Cancers 2012 ASCO Annual Meeting. J. Clin. Oncol. 30(Suppl.), :abstr LBA8509.
100. Robert, C., Thomas, L., Bondarenko, I., O'Day, S. M. D. J., Garbe, C., Lebbe, C., et al. (2011). Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N. Engl. J. Med. 364, 2517-2526.
101. Roberts, P. J., and Der, C. J. (2007). Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 26, 3291-3310.
102. Sakaizawa, K., Goto, Y., Kiniwa, Y., Uchiyama, A., Harada, K., Shimada, S., et al. (2012). Mutation analysis of BRAF and KIT in circulating melanoma cells at the single cell level. Br. J. Cancer 106, 939-946.
103. Schwartz, G. K., Robertson, S., Shen, A., Wang, E., Pace, L., Dials, H., et al. (2009). A phase I study of XL281, a selective oral RAF kinase inhibitor, in patients (Pts) with advanced solid tumors. Melanoma/Skin Cancers 2009 ASCO Annual Meeting. J. Clin. Oncol. 27(Suppl. 15s), :abstr 3513.
104. Sebti, S. M. (2005). Protein farnesylation: implications for normal physiology, malignant transformation, and cancer therapy. Cancer Cell 7, 297-300.
105. Sensi, M., Nicolini, G., Petti, C., Bersani, I., Lozupone, F., Molla, A., et al. (2006). Mutually exclusive NRASQ61R and BRAFV600E mutations at the single-cell level in the same human melanoma. Oncogene 25, 3357-3364.
106. Shi, H., Kong, X., Ribas, A., and Lo, R. S. (2011). Combinatorial treatments that overcome PDGFRbeta-driven resistance of melanoma cells to V600EB-RAF inhibition. Cancer Res. 71, 5067-5074.
107. Shi, H., Moriceau, G., Kong, X., Koya, R. C., Nazarian, R., Pupo, G. M., et al. (2012a). Preexisting MEK1 exon 3 mutations in V600E/KBRAF melanomas do not confer resistance to BRAF inhibitors. Cancer Discov. 2, 414-424.
108. Shi, H., Moriceau, G., Kong, X., Lee, M.-K., Lee, H., Koya, R. C., et al. (2012b). Melanoma whole-exome sequencing identifies V600EB-RAF amplification-mediated acquired B-RAF inhibitor resistance. Nat. Commun. 3, 724.
109. Sosman, J. A., Kim, K. B., Schuchter, L., Gonzalez, R., Pavlick, A. C., Weber, J. S., et al. (2012). Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N. Engl. J. Med. 366, 707-714.
110. Stark, M. S., Woods, S. L., Gartside, M. G., Bonazzi, V. F., Dutton-Regester, K., Aoude, L. G., et al. (2012). Frequent somatic mutations in MAP3K5 and MAP3K9 in metastatic melanoma identified by exome sequencing. Nat. Genet. 44, 165-169.
111. Stuart, D., and Sellers, W. R. (2009). Linking somatic genetic alterations in cancer to therapeutics. Curr. Opin. Cell Biol. 21, 304-310.
112. Su, F., Viros, A., Milagre, C., Trunzer, K., Bollag, G., Spleiss, O., et al. (2012a). RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N. Engl. J. Med. 366, 207-215.
113. Su, Y., Vilgelm, A. E., Kelley, M. C., Hawkins, O. E., Liu, Y., Boyd, K. L., et al. (2012b). RAF265 inhibits the growth of advanced human melanoma tumors. Clin. Cancer Res. 18, 2184-2198.
114. Taniguchi, K., Okami, J., Kodama, K., Higashiyama, M., and Kato, K. (2008). Intratumor heterogeneity of epidermal growth factor receptor mutations in lung cancer and its correlation to the response to gefitinib. Cancer Sci. 99, 929-935.
115. Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., et al. (2012). Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366, 2443-2454.
116. Ugurel, S., Hildenbrand, R., Zimpfer, A., La Rosee, P., Paschka, P., Sucker, A., et al. (2005). Lack of clinical efficacy of imatinib in metastatic melanoma. Br. J. Cancer 92, 1398-1405.
117. US Food and Drug Administration. (2011). FDA labelling information-Zelboraf. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/202429s000lbl.pdf
118. Van Raamsdonk, C. D., Griewank, K. G., Crosby, M. B., Garrido, M. C., Vemula, S., Wiesner, T., et al. (2010). Mutations in GNA11 in uveal melanoma. N. Engl. J. Med. 363, 2191-2199.
119. Venetsanakos, E., Stuart, D., Tan, N., Ye, H., Salangsang, F., Aardalen, K., et al. (2006). CHIR-265, a novel inhibitor that targets B-Raf and VEGFR, shows efficacy in a broad range of preclinical models. Proc. Amer. Assoc. Cancer Res. 47, abstr 4854.
120. Villanueva, J., Vultur, A., Lee, J. T., Somasundaram, R., Fukunaga-Kalabis, M., Cipolla, A. K., et al. (2010). Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell 18, 683-695.
121. von Mehren, M. (2006). Beyond imatinib: second generation c-KIT inhibitors for the management of gastrointestinal stromal tumors. Clin. Colorectal Cancer 6(Suppl. 1), S30-S34.
122. Wagle, N., Emery, C., Berger, M. F., Davis, M. J., Sawyer, A., Pochanard, P., et al. (2011). Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J. Clin. Oncol. 29, 3085-3096.
123. Webster, J. D., Kiupel, M., and Yuzbasiyan-Gurkan, V. (2006). Evaluation of the kinase domain of c-KIT in canine cutaneous mast cell tumors. BMC Cancer 6:85. doi:10.1186/1471-2407-6-85
124. Wei, X., Walia, V., Lin, J. C., Teer, J. K., Prickett, T. D., Gartner, J., et al. (2011). Exome sequencing identifies GRIN2A as frequently mutated in melanoma. Nat. Genet. 43, 442-446.
125. Wellbrock, C., Karasarides, M., and Marais, R. (2004). The RAF proteins take centre stage. Nat. Rev. Mol. Cell Biol. 5, 875-885.
126. Wilhelm, S., Carter, C., Lynch, M., Lowinger, T., Dumas, J., Smith, R. A., et al. (2006). Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat. Rev. Drug Discov. 5, 835-844.
127. Wilmott, J. S., Long, G. V., Howle, J. R., Haydu, L. E., Sharma, R. N., Thompson, J. F., et al. (2012). Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma. Clin. Cancer Res. 18, 1386-1394.
128. Wyman, K., Atkins, M. B., Prieto, V., Eton, O., McDermott, D. F., Hubbard, F., et al. (2006). Multicenter Phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacy. Cancer 106, 2005-2011.
129. Yancovitz, M., Litterman, A., Yoon, J., Ng, E., Shapiro, R. L., Berman, R. S., et al. (2012). Intra-and inter-tumor heterogeneity of BRAF(V600E) mutations in primary and metastatic melanoma. PLoS ONE 7:e29336. doi:10.1371/journal.pone.0029336
130. Yang, M. J., Chiu, H. H., Wang, H. M., Yen, L. C., Tsao, D. A., Hsiao, C. P., et al. (2010). Enhancing detection of circulating tumor cells with activating KRAS oncogene in patients with colorectal cancer by weighted chemiluminescent membrane array method. Ann. Surg. Oncol. 17, 624-633.
131. Yeh, T. C., Marsh, V., Bernat, B. A., Ballard, J., Colwell, H., Evans, R. J., et al. (2007). Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor. Clin. Cancer Res. 13, 1576-1583.